BBT-877
- Generic Name
- BBT-877
- Drug Type
- Small Molecule
- Background
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT05483907
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇦🇺Institute for Respiratory Health, Nedlands, Western Australia, Australia
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo single dose
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04138849
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bridge Biotherapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04138836
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath